First-Line, Non-Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti–β2-Glycoprotein I Domain I and Anti–Phosphatidylserine/Prothrombin Complex Antibodies Tests

Arthritis Care and Research

Volumn 70, Issue 4, 2018, Pages 627-634

  Nakamura, Hiroyuki ^a   Oku, Kenji ^a   Amengual, Olga ^a   Ohmura, Kazumasa ^a   Fujieda, Yuichiro ^a   Kato, Masaru ^a   Bohgaki, Toshiyuki ^a   Yasuda, Shinsuke ^a   Atsumi, Tatsuya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHATIDYLSERINE ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY; UNCLASSIFIED DRUG; BETA2 GLYCOPROTEIN 1; PHOSPHATIDYLSERINE; PROTHROMBIN;

ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; RETROSPECTIVE STUDY; THROMBOSIS; BLOOD; EVALUATION STUDY; IMMUNOLOGY; PROCEDURES; REPRODUCIBILITY; SEROLOGY;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; PHOSPHATIDYLSERINES; PREDICTIVE VALUE OF TESTS; PROTHROMBIN; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEROLOGIC TESTS;

EID: 85044655916     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23310     Document Type: Article

References (39)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.
2. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994;179:457–62.
3. Devreese K, Hoylaerts MF. Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome. Eur J Haematol 2009;83:1–16.
4. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GR. Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996;35:1239–43.
5. Hunt JE, McNeil HP, Morgan GJ, Crameri RM, Krilis SA. A phospholipid-β2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992;1:75–81.
6. Arvieux J, Regnault V, Hachulla E, Darnige L, Roussel B, Bensa JC. Heterogeneity and immunochemical properties of anti-β2-glycoprotein I autoantibodies. Thromb Haemost 1998;80:393–8.
7. George J, Gilburd B, Hojnik M, Levy Y, Langevitz P, Matsuura E, et al. Target recognition of β2-glycoprotein I (β2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of β2GPI in antibody binding. J Immunol 1998;160:3917–23.
8. Adams M. Measurement of lupus anticoagulants: an update on quality in laboratory testing. Semin Thromb Hemost 2013;39:267–71.
9. Triplett DA. Many faces of lupus anticoagulants. Lupus 1998;7 Suppl 2:S18–22.
10. 2-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum 2007;56:280–90.
11. Zager U, Kveder T, Cucnik S, Bozic B, Lunder M. Anti-β2-glycoprotein I paratopes and β2-glycoprotein I epitopes characterization using random peptide libraries. Autoimmunity 2014;47:438–44.
12. Banzato A, Pozzi N, Frasson R, de Filippis V, Ruffatti A, Bison E, et al. Antibodies to domain I of β(2)glycoprotein I are in close relation to patients risk categories in antiphospholipid syndrome (APS). Thromb Res 2011;128:583–6.
13. De Laat B, Pengo V, Pabinger I, Musial J, Voskuyl AE, Bultink IE, et al. The association between circulating antibodies against domain I of β2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 2009;7:1767–73.
14. De Laat B, Derksen RH, van Lummel M, Pennings MT, de Groot PG. Pathogenic anti-β2-glycoprotein I antibodies recognize domain I of β2-glycoprotein I only after a conformational change. Blood 2006;107:1916–24.
15. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66:629–32.
16. Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988;72:512–9.
17. Hoxha A, Ruffatti A, Mattia E, Meneghel L, Tonello M, Salvan E, et al. Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. Clin Chem Lab Med 2015;53:1265–70.
18. Pregnolato F, Chighizola CB, Encabo S, Shums Z, Norman GL, Tripodi A, et al. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS? Immunol Res 2013;56:432–8.
19. Horita T, Ichikawa K, Kataoka H, Yasuda S, Atsumi T, Koike T. Human monoclonal antibodies against the complex of phosphatidylserine and prothrombin from patients with the antiphospholipid antibodies. Lupus 2007;16:509–16.
20. Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982–93.
21. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome: a systematic review. Thromb Haemost 2014;111:354–64.
22. Vlagea A, Gil A, Cuesta MV, Arribas F, Diez J, Lavilla P, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome. Clin Appl Thromb Hemost 2013;19:289–96.
23. Zigon P, Cucnik S, Ambrozic A, Kveder T, Semrl SS, Rozman B, et al. Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value. Clin Dev Immunol 2013;2013:724592.
24. Zigon P, Perdan Pirkmajer K, Tomsic M, Kveder T, Bozic B, Sodin Semri S, et al. Anti-phosphatidylserine/prothrombin antibodies are associated with adverse pregnancy outcomes. J Immunol Res 2015;2015:975704.
25. Marchetti T, de Moerloose P, Gris JC. Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. J Thromb Haemost 2016;14:675–84.
26. Pengo V, Ruffatti A, Tonello M, Cuffaro S, Banzato A, Bison E, et al. Antiphospholipid syndrome: antibodies to domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 2015;13:782–7.
27. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987;68:215–22.
28. Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 2014;12:792–5.
29. Brandt JT, Triplett DA, Alving B, Scharrer I, on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995;74:1185–90.
30. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al, for the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009;7:1737–40.
31. Otomo K, Atsumi T, Amengual O, Fujieda Y, Kato M, Oku K, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum 2012;64:504–12.
32. Meneghel L, Ruffatti A, Gavasso S, Tonello M, Mattia E, Spiezia L, et al. Detection of IgG anti-domain I β2 glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clin Chim Acta 2015;446:201–5.
33. De Craemer AS, Musial J, Devreese KM. Role of anti–domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost 2016;14:1779–87.
34. Pelkmans L, Kelchtermans H, de Groot PG, Zuily S, Regnault V, Wahl D, et al. Variability in exposure of epitope G40-R43 of domain I in commercial anti-β2-glycoprotein I IgG ELISAs. PLoS One 2013;8:e71402.
35. Mondejar R, Gonzalez-Rodriguez C, Toyos-Saenz de Miera FJ, Melguizo-Madrid E, Zohoury N, Mahler M, et al. Role of antiphospholipid score and anti-β2-glycoprotein I domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin Chim Acta 2014;431:174–8.
36. Mahler M, Albesa R, Zohoury N, Bertolaccini ML, Ateka-Barrutia O, Rodriguez-Garcia JL, et al. Autoantibodies to domain 1 of β 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome. Lupus 2016;25:911–6.
37. Atsumi T, Amengual O, Yasuda S, Koike T. Antiprothrombin antibodies: are they worth assaying? Thromb Res 2004;114:533–8.
38. Sciascia S, Cuadrado MJ, Sanna G, Murru V, Roccatello D, Khamashta MA, et al. Thrombotic risk assessment in systemic lupus erythematosus: validation of the Global Antiphospholipid Syndrome Score in a prospective cohort. Arthritis Care Res (Hoboken) 2014;66:1915–20.
39. Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005;93:1147–52.